📰 Risk Evaluation News
Page 29 - Risk Evaluation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Risk Evaluation. Real-time updates on events, politics, business and more.
May 30, 2023
Pivotal trials TRANSCEND FL and TRANSCEND NHL 001 continue to underscore the transformative potential of Breyanzi and its clinically meaningful benefit across the broadest array of B-cell... | May 30, 2023
May 30, 2023
RARITAN, NJ,May 30, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a New Drug Application to the U.S. Food and Drug Administration ... | May 30, 2023
May 26, 2023
Advocates at Alliance for Health Policy briefing called for increased awareness, new therapies
May 25, 2023
The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed
May 25, 2023
The application to the European Medicines Agency is supported by data from the Phase 3 CARTITUDE-4 study, evaluating the safety and efficacy of cilta-cel in the treatment of patients with relapsed... | May 25, 2023
May 25, 2023
The abortion pill's safety has been repeatedly called into question by pro-life doctors and advocates since the FDA's approval in 2000 of mifepristone.
May 25, 2023
TRANSCEND CLL 004 is the first pivotal multicenter trial to evaluate a CAR T cell therapy in heavily pre-treated patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic... | May 25, 2023
May 24, 2023
The FDA announced that it has approved Brixadi, an extended-release subcutaneous injection for the treatment of moderate to severe opioid use disorder.Brixadi (buprenorphine, Braeburn Inc.) is the first long-acting buprenorphine injectable that can be given in weekly or monthly doses to patients with opioid use disorder (OUD) who have already initiated treatment with transmucosal buprenorphine or
May 24, 2023
Brixadi (buprenorphine) is approved for patients with moderate to severe OUD who are already taking or have initiated transmucosal buprenorphine.
May 23, 2023
BALTIMORE — A special late-breaking session at the ACOG Annual Scientific & Clinical meeting featured the most up-to-date information and guidance on availability of the abortion drug mifepristone. Kristyn M. Brandi, MD, MPH, FACOG, the Darney-Landy Fellow at ACOG for 2022-2023 and OB/GYN physician and complex family planning subspecialist, discussed the current controversy